Skip to main content

Table 1 Baseline demographic and disease characteristics

From: Existing joint erosions increase the risk of joint space narrowing independently of clinical synovitis in patients with early rheumatoid arthritis

Baseline characteristic MTX ADA ADA + MTX
(n = 202) (n = 203) (n = 226)
Age, years 52.7 ± 13.3 52.0 ± 12.9 52.0 ± 14.1
Female, n (%) 149 (73.8) 154 (75.9) 159 (70.4)
Disease duration, years 0.8 ± 0.9 0.7 ± 0.8 0.7 ± 0.8
Rheumatoid factor-positive, n (%) 172 (85.6) 172 (84.7) 191 (84.5)
Prior DMARD use, n (%) 61 (30.2) 68 (33.5) 69 (30.5)
Baseline corticosteroid use, n (%) 68 (33.7) 74 (36.5) 81 (35.8)
SJC (0 to 66) 22.3 ± 12.0 21.6 ± 10.4 21.4 ± 11.5
TJC (0 to 68) 32.0 ± 14.3 32.5 ± 13.8 30.5 ± 14.5
DAS28-CRP (0 to 10) 6.3 ± 0.9 6.3 ± 0.9 6.3 ± 0.9
DAS28-CRP ≥5.1, n (%) 183 (93.4) 177 (88.9) 196 (90.3)
HAQ-DI (0 to 3) 1.5 ± 0.7 1.6 ± 0.6 1.5 ± 0.6
CRP, mg/dL 4.0 ± 4.0 3.8 ± 3.6 3.9 ± 4.1
mTSS (0 to 398) 22.5 ± 22.6 19.0 ± 18.9 18.7 ± 20.7
JE (0 to 230)a 14.0 ± 13.7 11.5 ± 11.5 11.4 ± 12.9
JSN (0 to 168) 8.5 ± 10.9 7.5 ± 8.8 7.3 ± 9.4
  1. All values are mean ± SD, unless otherwise indicated. a P = 0.047 for pairwise comparison of MTX versus ADA + MTX. MTX, methotrexate; ADA, adalimumab; DMARD, disease-modifying antirheumatic drug; SJC, swollen joint count; TJC, tender joint count; DAS28, 28-joint disease activity score; HAQ-DI, disability index of the health assessment questionnaire; CRP, C-reactive protein; mTSS, modified total Sharp score; JE, joint erosion; JSN, joint space narrowing.